Abstract
BackgroundRecently, equine multipotent mesenchymal stromal cells (MSC) have received significant attention as therapy for various conditions due to their proposed regenerative and immune-modulating capacity. MSC are commonly administered to the patient through a hypodermic needle. Currently, little information is available on the effect of such injection has on equine MSC immediate and delayed viability. We hypothesize that viability of equine MSC is not correlated with needle diameter during aspiration and injection.ResultsUsing a 3 mL syringe, manual injection of equine cord blood (CB) or bone marrow-derived (BM) MSC with no needle and needles ranging in size from 18 to 30 Ga did not affect immediate MSC viability. Similarly, 24 h post-injection, MSC delayed viability was not different between any of the tested needles as determined by a resazurin-based proliferation assay. Using a 3 mL syringe, aspiration of MSC through 20, 25, and 30 Ga needles resulted in significant decreases in immediate viability with no change in delayed viability when compared to aspiration without a needle. BM- and CB-MSC were observed to be of similar size with a diameter ± SD of 19.8 ± 2.7 and 20.4 ± 2.2 μm, respectively. In comparison, the smallest needles, (30 Ga) have an internal diameter of 160 μm.ConclusionsFollowing injection, needle diameter did not affect immediate or delayed viability of equine MSC. Following aspiration through needles sizes 20 Ga and smaller, immediate viability, but not delayed viability, decreased. As a result, an 18 Ga or larger needle should be utilized for aspiration of cell suspensions. In contrast, needle selection for MSC injection should be based on clinical preference and experience rather than concerns over decreasing MSC viability.
Highlights
Equine multipotent mesenchymal stromal cells (MSC) have received significant attention as therapy for various conditions due to their proposed regenerative and immune-modulating capacity
Immediate viability was significantly increased in MSC injected through 25 Ga needles (p = 0.01), Fig. 1a
There was no difference between cells originating from bone marrow-derived (BM) or cord blood (CB), and no interaction was detected between MSC source and needle gauge
Summary
Equine multipotent mesenchymal stromal cells (MSC) have received significant attention as therapy for various conditions due to their proposed regenerative and immune-modulating capacity. We hypothesize that viability of equine MSC is not correlated with needle diameter during aspiration and injection. The current practice of MSC therapy requires administration of a cell-based suspension into the target tissue or structure by injection through a hypodermic needle. In order for stem cells to retain their potential benefits, One of the defining characteristics of MSC is their ability to adhere to tissue culture-treated polystyrene plastic. In order for MSC to be used as a therapeutic agent, they must be detached from the culture flask and suspended in liquid prior to injection. This process results in spindle-shaped adherent MSC transforming into spherical free-floating MSC. The diameter of Williams et al BMC Veterinary Research (2016) 12:45
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
